Tumor-associated antigen xage-1b short peptide and its application

Abstract

The invention discloses a tumor-associated antigen XAGE-1b short-peptide and application thereof. The sequences of the short-peptide is one of the SEQ ID NO:2-SEQ ID NO:15. The CTL induced by the XAGE-1b antigen peptide does not produce an immune response to testicular cells, and only kills tumor cells. The obtained CTL clone has a good specific killing effect on tumor cells. The selected XAGE-1b antigen peptide has comparable affinity to HLA on DC cells and can effectively stimulate and induce specific CTLs, indicating that the selected XAGE-1b antigen peptide has good potential of polypeptide vaccine and DC vaccine. By cloning XAGE-1b antigen peptide specific TCR gene, constructing viral vector, transducing peripheral circulation CD8+T cells, TCR gene modified T cells (TCR-T) clone is obtained, and also has specific killing effect on tumor cells which is similar to parental CTL, suggesting that the XAGE-1b short-peptide has good clinical application and transformation prospect.

Description

technical field [0001] The invention relates to tumor-associated antigen peptides and applications thereof, in particular to tumor-associated antigen XAGE-1b short peptides and applications thereof. Background technique [0002] As we all know, T cell adoptive therapy for tumors is currently the most eye-catching technology, especially the application of receptor-engineered T cells is becoming an exciting cancer treatment method, and it also has broad application prospects for viral infections and autoimmune diseases. [0003] The human immune surveillance system plays an important role in the process of resisting tumor growth. The immune surveillance system achieves the purpose of inhibiting tumor growth by coordinating various types of immune cells, among which cytotoxic T cells (cytotoxic Tlymphocytes, CTLs) play an extremely important role and are the most important. Key killer effector cells. tumor antigen-specific CD8 + T cells can specifically recognize and directly...

AI Technical Summary

Problems solved by technology

In the technical scheme disclosed by CN102428102A, an attempt is made to intercept a part of the XAGE-1b antigen to induce humoral immunity or cellular immunity to the tumor, but the result is not satisfactory, and the length of the polypeptide is still not shorter than 16AA

[0013] Short peptides may also have the problem of poor specificity. How to obtain short peptides with good specificity and good immunogenicity is a very challenging task

Images